ALLEGAN, Mich. — Padagis has been selected by the New York State Department of Health as its supplier of naloxone, the medication used to reverse opioid overdoses. The agreement will expand access to the life-saving treatment while significantly lowering costs for taxpayers across the state.
By purchasing a generic naloxone product, New York State expects to save millions in healthcare spending, with those savings helping to fund expanded overdose prevention programs and outreach. Padagis Naloxone Nasal Spray 4 mg delivers the same bioavailability and effectiveness as its brand-name equivalent, offering an affordable and reliable option for communities across the state.
“While New York’s opioid overdose rates are finally trending in the right direction, it’s critical that we keep building on that momentum by ensuring naloxone is within reach for every community,” said Senator Nathalia Fernandez. “By turning to generic naloxone, we’re stretching every public-health dollar further without sacrificing quality or effectiveness. These savings mean more doses, broader access, and ultimately, more lives saved.”
Pamela Hoffman, President of Padagis, praised the state’s approach to striking a balance between fiscal responsibility and public health. “We applaud New York State for taking this important step to expand access to life-saving medicine through generic options,” Hoffman said. “Padagis was founded on the belief that high-quality generics can and should play a vital role in public health. By choosing a generic supplier, New York is not only reducing costs but helping ensure more doses of naloxone reach the people who need it most.”
Based in Allegan, Michigan, Padagis is a leading provider of extended topical and specialty medications. The company employs over 1,300 people worldwide and is committed to improving healthcare accessibility through affordable, high-quality medicines, including its flagship over-the-counter naloxone nasal spray —a key tool in combating the opioid crisis.
For more information, visit www.padagis.com.
